Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Micromedic Technologies

Events

08 Feb 2016 - 10 Feb 2016
11 Feb 2016 - 12 Feb 2016
18 Feb 2016 - 20 Feb 2016

Next Gen Sequencing Generates High Quality Data

By Labmedica International staff writers
Posted on 03 Jan 2012
Print article
A leader in clinical diagnostics and genomic services has officially launched its Next-Gen sequencing services.

Scientists have a wide range of sequencing read options ranging from 36 base pair (bp) singleton to 150 bp paired-end reads. The system is capable of generating over 2 gigabyte (GB) data per run with a high percentage of bases over Q30.

The high data yield and superior quality allows scientists to conduct a wide variety of sequencing applications including: highly multiplexed polymerase chain reaction (PCR) amplicon sequencing, small genome sequencing and de novo sequencing, small RNA sequencing, targeted resequencing, and 16S metagenomics.

Ambry Genetics (Aliso Viejo, CA, USA) has officially launched their Next-Gen sequencing services Illumina MiSeq. Ambry Genetics has been an adapter of Illumina (San Diego, CA, USA) sequencing systems for several years and has extensive experience as a Certified Service Provider processing thousands of samples. The Illumina MiSeq uses the same established reversible-terminator sequencing by synthesis chemistry as the HiSeq2000.

"The MiSeq is a fully integrated sequencing platform enabling up to 2 GB of sequencing data using Illumina's established and reliable TruSeq technology. The quick run time and high data yield make the system ideal for amplicon and targeted resequencing projects," said Dr. Aaron Elliott, Director of Genomic Services.

Ambry Genetics is a College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified commercial clinical laboratory. It has become a leader in providing genetic services focused on clinical diagnostics and genomic services, particularly sequencing and array services.

Related Links:
Ambry Genetics
Illumina



Print article

Channels

Immunology

view channel
Image: Micrograph of prostatic adenocarcinoma with perineural invasion, conventional (acinar) type, the most common form of prostate cancer. Prostate biopsy, H&E stain (Photo courtesy of Nephron and Wikimedia).

Reduced PSA Screening May Delay Treatment for Earlier Onset Prostate Cancers

The recommendation against regular prostate specific antigen (PSA) screening for prostate cancer (PCa) has been in place for 2.5 years. The number of prostate needle biopsies (PNB) has been reduced and... Read more

Industry News

view channel

Abbott to Gain Leadership in POC Diagnostics upon Acquisition of Alere

Abbott Inc. (Abbott Park, IL, USA) and Alere Inc. (Waltham, MA, USA) have reached a definitive agreement under which Abbott will pay an equity value of about USD 5.8 billion to acquire Alere. Once the transaction is completed, Abbott will become leading diagnostics provider of point-of-care (POC) testing.... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.